The Pioneers of GLP-1 Drugs: Who Invented Them and Their Impact on Weight Loss

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The development of GLP-1 medications marks a watershed moment in clinical medicine, with semaglutide demonstrating up to 22% body weight reduction in landmark trials. These medications grew from fundamental research into glucagon-like peptide-1, a hormone that regulates blood sugar and appetite. Today, compounded versions from licensed pharmacies make this science accessible without insurance or membership requirements.

The Scientific Origin of GLP-1 Receptor Agonists

In 1987, researchers identified glucagon-like peptide-1 as a hormone released by intestinal cells after eating. This discovery sparked decades of investigation into how GLP-1 signals the pancreas and brain to control blood glucose and satiety. Scientists recognized that mimicking this natural pathway could address both metabolic disorders and weight management.

The first GLP-1 receptor agonist, exenatide, reached patients in 2005 after showing meaningful improvements in type 2 diabetes control. This synthetic peptide opened a new therapeutic class and proved that activating the GLP-1 pathway could produce sustained metabolic benefits. Subsequent generations of medications refined potency, duration, and tolerability, leading to more effective compounds like semaglutide.

Semaglutide: From Diabetes Treatment to Weight Loss Breakthrough

Semaglutide emerged in the mid-2010s as a long-acting GLP-1 agonist designed for once-weekly dosing in diabetes patients. Researchers noticed a striking side effect: participants consistently lost substantial body weight, far exceeding typical weight management interventions. This observation shifted focus toward semaglutide's potential as a standalone weight loss therapy, independent of diabetes diagnosis.

The STEP trial program, conducted from 2018 to 2021, enrolled over 4,600 adults with obesity or weight-related conditions. Participants receiving semaglutide lost an average of 15 kg (33 pounds) compared to 2.6 kg in the placebo group over 68 weeks. These results demonstrated that semaglutide could produce durable, clinically meaningful weight reduction when combined with lifestyle modifications.

How GLP-1 Drugs Regulate Appetite and Metabolism

GLP-1 receptor agonists work through multiple biological pathways simultaneously. These medications bind to GLP-1 receptors throughout the gastrointestinal tract and brain, slowing gastric emptying and signaling fullness to appetite centers in the hypothalamus. The result is naturally reduced food intake without requiring constant willpower or dietary restriction.

Beyond appetite suppression, semaglutide enhances insulin secretion in response to meals, improving how the body processes glucose. It also promotes weight loss through subtle shifts in energy expenditure and may improve cardiovascular function through mechanisms independent of weight reduction. This multifaceted approach explains why GLP-1 agonists produce effects that single-mechanism diet drugs cannot achieve.

Accessing Semaglutide Through PlexusDx: Modern Precision Weight Loss

PlexusDx provides compounded semaglutide injection from licensed 503A pharmacies, starting at $149 per month with no insurance requirement or membership fees. The medication is HSA/FSA eligible, making it accessible to patients across diverse financial circumstances. PlexusDx serves all 50 states and handles prescriptions through licensed healthcare providers who assess candidacy and dosing needs.

To optimize outcomes, PlexusDx offers the Precision Peptide Genetic Test as a $99 add-on after the first month of treatment. This peptide-pathway genetic assessment examines variants like GLP1R rs6923761 and MC4R rs17782313 that influence individual response to GLP-1 therapy. Understanding these genetic factors helps personalize treatment protocols and predict which patients may benefit most from semaglutide or alternative formulations.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Who invented GLP-1 medications and when did they first become available?

Researchers identified glucagon-like peptide-1 as a hormone in 1987, leading to exenatide's FDA approval in 2005 as the first GLP-1 receptor agonist. Semaglutide followed in the 2010s, initially for diabetes and later approved for weight loss based on landmark STEP trials showing up to 22% body weight reduction.

What clinical evidence supports semaglutide for weight loss?

The STEP trial program involved over 4,600 adults and demonstrated that semaglutide produced average weight loss of 15 kg over 68 weeks, compared to 2.6 kg in the placebo group. These sustained results were achieved with once-weekly injection and lifestyle support, establishing semaglutide as a clinically validated weight management option.

How much does PlexusDx compounded semaglutide cost per month?

PlexusDx offers compounded semaglutide injection starting at $149 per month across all commitment tiers, with no flat per-compound pricing increases. Your dose may need to go up over time as your body adjusts, but your price won't. The medication is available without insurance, membership fees, or prior authorization across all 50 states.

Are there genetic factors that influence how well semaglutide works for me?

Yes. The PlexusDx Precision Peptide Genetic Test ($99 add-on) examines 14 pathways and 150+ genetic insights, including the GLP1R rs6923761 and MC4R rs17782313 variants that influence GLP-1 response and weight loss potential. This personalized data helps your provider optimize your treatment protocol for maximum effectiveness.

Is compounded semaglutide from PlexusDx as safe as brand-name versions?

PlexusDx sources compounded semaglutide exclusively from licensed 503A compounding pharmacies, which operate under strict quality and sterility standards. While compounded medications are not FDA-approved, 503A pharmacies are regulated by state pharmacy boards and the FDA. Your PlexusDx provider conducts a complete medical assessment before prescribing to ensure safety and appropriate dosing for your individual health profile.

Related Reading

• Glp 1 Drugs For Weight Loss
• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.